CTNNB1 and ovarian carcinoma: Interestingly, it has been shown that the FDA-approved Wnt inhibitor pyrvinium pamoate, which down-regulates CTNNB1, synergizes with the PARP inhibitor olaparib in ovarian cancer cells and PDX models [32].